Medicare locks its drug-price negotiation into permanent regulation
CMS finalised the rule codifying the Medicare Drug Price Negotiation Program on 9 November, replacing guidance with binding regulation from the 2029 negotiation cycle. The rule takes effect 5 December 2026.
The Centers for Medicare & Medicaid Services has finalised the rule that turns the Medicare Drug Price Negotiation Program from a programme run on guidance into one run on binding regulation. The final rule, published in the Federal Register on 9 November 2026 under docket CMS-4215-F, codifies the Negotiation Program and sets certain new policies for it and for the Medicare Part D benefit, as required by the Inflation Reduction Act of 2022 [s1]. The regulations take effect on 5 December 2026 [s1].
What changes, and when
The programme itself is not new. Since the Inflation Reduction Act gave Medicare authority to negotiate prices directly with manufacturers, CMS has implemented it largely through non-binding final guidance, most recently the guidance for initial price applicability year 2028 [s1]. This rule codifies those mechanics in regulation at 42 CFR Parts 423 and 429 [s1].
The timing is forward-looking. CMS states the regulations are applicable to the Negotiation Program beginning with initial price applicability year 2029, and to Part D coverage beginning 1 January 2029 [s1]. In other words, the rule does not reopen prices already negotiated; it governs the cycle that produces prices taking effect in 2029 and the cycles after it.
The scale written into the rule
The rule restates the statutory ceiling on how many drugs can be negotiated. CMS says the Secretary will select up to 20 drugs covered under Part D or payable under Part B, or both, for initial price applicability year 2029 and subsequent years [s1]. That is a ceiling on volume, not a guaranteed number; which products are selected each year turns on the programme's spending thresholds and eligibility rules.
The rule also sets out, in regulation, the core steps the statute assigns to CMS: publishing a list of selected drugs, entering into agreements with the manufacturers of those drugs, negotiating a maximum fair price for each, and publishing those prices [s1].
The finalised policies
Three changes stand out among the provisions CMS finalised. First, it finalised the section governing a Temporary Floor for Small Biotech Drugs, to be implemented for initial price applicability years 2029 and 2030, modifying its proposed stepwise approach for calculating a selected drug's ceiling where certain ceiling amounts fall below that floor [s1]. Second, it clarified when off-label use would be considered for renegotiation eligibility and selection, aligning the renegotiation policies with the initial-offer development process [s1]. Third, it finalised a policy for specific fixed-combination drugs that are new formulations [s1].
The rule also sets out how CMS will calculate a 30-day equivalent supply for a selected drug or therapeutic alternative payable under Part B that is typically administered one time, naming some vaccines, gene therapies and cancer therapies as examples [s1].
Why guidance versus regulation matters
The practical difference between guidance and codified regulation is durability and process. Guidance documents can be revised more readily than regulations, which must move through notice-and-comment rulemaking to be changed. By finalising this rule, CMS moves the programme's operating rules into that more formal footing, where the earlier proposed rule, published on 16 June 2026 under the same regulation identifier RIN 0938-AV90, had set out what the agency intended and invited comment [s2].
What is settled
What this rule fixes is concrete. A dated final rule now exists, it codifies the Negotiation Program in regulation at 42 CFR Parts 423 and 429, it takes effect on 5 December 2026, and it applies to the Negotiation Program beginning with initial price applicability year 2029 and to Part D coverage beginning 1 January 2029 [s1]. The up-to-20-drug ceiling, the small-biotech floor for 2029 and 2030, the renegotiation and fixed-combination policies are now in the regulatory text [s1].
What the rule does not do is name any drug or set any price. Selection and the negotiated maximum fair prices are carried out through the programme's annual cycles under the statutory process the rule codifies, not by this rule itself [s1]. Its weight lies in moving the programme's rules from guidance into regulation and settling the policies that the 2029 cycle and those after it will run on [s1].
Sources
- Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program (Final Rule) — Centers for Medicare & Medicaid Services / Federal Register , November 9, 2026
- Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program (Proposed Rule) — Centers for Medicare & Medicaid Services / Federal Register , June 16, 2026
Medicare sets 2027 dialysis base rate at $297.52 and folds in phosphate binders
CMS finalised the End-Stage Renal Disease payment system for 2027 on 30 October, lifting the per-treatment base rate from $281.71 and raising total dialysis payments by about $245 million.
CMS proposes $0 Part D copay for poorest dual eligibles and new PBM rules
A proposed rule would cut the Part D generic copay from $1 to $0 for the lowest-income dual eligibles in 2028, tighten Medicare Advantage directory accuracy, and add PBM transparency rules. Comments close 15 December.
Medicare's first negotiated drug prices cut 10 drugs 38% to 79%, from 2026
The prices apply only to 10 drugs, only in Medicare, and only from January 2026. Here is exactly which drugs, by how much, and who actually sees the difference.
Medicare finalises 2027 physician pay as both conversion factors are set to fall
CMS published the CY 2027 Physician Fee Schedule final rule on 9 November. Statutory updates are 0.75 percent for advanced-model clinicians and 0.25 percent for others, yet both conversion factors are projected to drop.